2020 ASCO Virtual Direct™ Highlights
Playback speed
10 seconds
2020 ASCO Update on ctDNA: Can We Use ctDNA as a Marker of MRD Following Definitive Treatment in Localized NSCLC? Is the Absence of Detectable BRAFV600 ctDNA at Baseline Associated With Improved PFS and OS in Pts Receiving Dabrafenib and Trametinib?
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Martin Dietrich
By
2020 ASCO Virtual Direct™ Highlights
FEATURING
Martin Dietrich
125 views
November 11, 2020
Comments 0
Login to view comments.
Click here to Login
Lung